CARLSBAD, Calif., Jan. 29 Ardea Biosciences,Inc. (Nasdaq: RDEA) today announced that preclinical data on the Company'snon-nucleoside reverse transcriptase inhibitor (NNRTI) family of compounds,including RDEA806, RDEA427 and RDEA640, will be presented during the 15thAnnual Conference on Retroviruses and Opportunistic Infections (CROI) inBoston, February 3-6, 2008.
RDEA806 is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI)for the potential treatment of HIV infection. Based on preclinical andclinical studies to-date, Ardea believes that RDEA806 possesses severalattractive properties. These include: potential for potent antiviral activityagainst a wide range of HIV viral isolates, including those that are resistantto efavirenz (Sustiva(R)), Bristol-Myers Squibb) and other currently availableNNRTIs; a high genetic barrier to resistance; the potential to be administeredin a patient-friendly, oral dosing regimen; limited pharmacokineticinteractions with other drugs; and the ability to be co-formulated with otherHIV antiviral drugs.
About Ardea Biosciences, Inc.
Ardea Biosciences of Carlsbad, California is a biotechnology companyfocused on the discovery and development of small-molecule therapeutics invirology, oncology and inflammation. The Company has two product candidates inclinical development and several others in preclinical development. Ardea'smost advanced clinical development candidate is RDEA806, a non-nucleosidereverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for thetreatment of HIV. In addition, the Company is also investigating RDEA806 forthe treatment of gout. In oncology, the Company is investigating amitogen-activated ERK kinase (MEK) inhibitor, RDEA119, in a Phase 1 study inadvanced cancer patients. Ardea also is developing a next-generation NNRTI forHIV and a next-generation MEK inhibitor for both cancer and inflammatorydiseases.
Statements contained in this press release regarding matters that are nothistorical facts are "forward-looking statements" within the meaning of thePrivate Securities Litigation Reform Act of 1995. Because such statements aresubject to risks and uncertainties, actual results may differ materially fromthose expressed or implied by such forward-looking statements. Such statementsinclude, but are not limited to, statements regarding: Ardea's goals,including the expected properties and benefits of RDEA806, RDEA119 and itsother compounds and the results of clinical and other studies. Risks thatcontribute to the uncertain nature of the forward-looking statements include:risks related to the outcomes of preclinical and clinical trials, risksrelated to regulatory approvals, delays in commencement of preclinical andclinical tests, and costs associated with internal development andin-licensing activities. These and other risks and uncertainties are describedmore fully in Ardea's most recently filed SEC documents, including its AnnualReport on Form 10-K and Quarterly Reports on Form 10-Q, under the headings"Risk Factors." All forward-looking statements contained in this press releasespeak only as of the date on which they were made. Ardea undertakes noobligation to update such statements to reflect events that occur orcircumstances that exist after the date on which they were made.The presentation details are as follows: Date/Time: Tuesday, February 5, 2008, 1:00 p.m. Eastern Standard Time Title: An IQ Assessment of RDEA806, A Potent NNRTI with an Excellent Activity Profile in the Presence of Human Serum Proteins Location: Poster Session 123 (Poster # 731) -- Hall A, Hynes Convention Center Date/Time: Tuesday, February 5, 2008, 1:00 p.m. Eastern Standard Time Title: RDEA427 and RDEA640 are Novel NNRTIs with Potent Anti-HIV Activity against NNRTI-Resistance Viruses Location: Poster Session 123 (Poste